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Delphi study
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Abstract
Background: Growth restriction in the newborn (GRN) can predispose to severe complications including
hypoglycemia, sepsis, and necrotizing enterocolitis. Different interventions and treatments, such as feeding
strategies, for GRN have specific benefits and risks. Comparing results from studies investigating intervention
studies in GRN is challenging due to the use of different baseline and study characteristics and differences in
reported study outcomes. In order to be able to compare study results and to allow pooling of data, uniform
reporting of study characteristics (minimum reporting set [MRS]) and outcomes (core outcome set [COS]) are
needed. We aim to develop both an MRS and a COS for interventional and treatment studies in GRN.
Methods/design: The MRS and COS will be developed according to Delphi methodology. First, a scoping literature
search will be performed to identify study characteristics and outcomes in research focused on interventions/treatments
in the GRN. An international group of stakeholders, including experts (clinicians working with GRN, and researchers who
focus on GRN) and lay experts ([future] parents of babies with GRN), will be questioned to rate the importance of the
study characteristics and outcomes in three rounds. After three rounds there will be two consensus meetings: a face-to-
face meeting and an electronic meeting. During the consensus meetings multiple representatives of stakeholder groups
will reach agreement upon which study characteristics and outcomes will be included into the COS and MRS. The
second electronic consensus meeting will be used to test if an electronic meeting is as effective as a face-to-face
meeting.
Discussion: In our opinion a COS alone is not sufficient to compare and aggregate trial data. Hence, to ensure
optimum comparison we also will develop an MRS. Interventions in GRN infants are often complicated by coexisting
preterm birth. A COS already has been developed for preterm birth. The majority of GRN infants are born at term,
however, and we therefore chose to develop a separate COS for interventions in GRN, which can be combined (with
expected overlap) in intervention studies enrolling preterm GRN babies.
Trial registration: Not applicable. This study is registered in the Core Outcome Measures for Effectiveness (COMET)
database. Registered on 30 June 2017.
Keywords: Growth restriction in the newborn, GRN, Fetal growth restriction, FGR, Intervention, Core outcome set, COS,
Minimum reporting set, MRS
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Background
Growth restriction in the newborn (GRN) is the post-par-
tum equivalent of fetal growth restriction (FGR) [1]. Opti-
mizing care of the GRN may positively influence the
degree of adverse outcomes in the long-term. Many inter-
ventions and treatments for neonates born with growth
restriction are symptom-driven, such as for hypothermia
and preterm birth. Currently, the most common specific
interventions for GRN are feeding strategies. Optimized
postnatal feeding strategies are aimed at enhancing growth
and reducing the incidence of short-term complications
such as hypoglycemia, sepsis, and necrotizing enterocolitis
(NEC) [2, 3] and long-term neurodevelopmental outcome
(including IQ). Positive immediate effects (faster growth)
may, however, have a potential negative trade-off for
metabolic health (obesity, cardiovascular risk) [4].
Different interventions and treatments have their own/
specific benefits and risks [2, 3, 5]. Comparing the results
from these studies is challenging due to the use of different
baseline and study characteristics and also because of dif-
ferences in reported study outcomes [6]. In order to be
able to compare study results and to allow pooling of data,
uniform reporting of study characteristics (minimum
reporting set [MRS]) and of outcomes (core outcome set
[COS]) are needed.
An MRS considers the study and population (baseline)
characteristics that should, as a minimum, be reported,
such as the study population, the details of the interven-
tion, the references and what exactly is under study. An
MRS for FGR has been developed [7], but this has not
yet been performed for studies in GRN. A COS is a min-
imal set of outcomes that needs to be measured on a
certain topic [8]. A COS for FGR also has been devel-
oped [9], but this has also not yet been performed for in-
terventions and treatments for GRN.
We aim to develop both a COS and an MRS for GRN
using the Delphi methodology according to the COMET
initiative [8–10]. Their development will be informed by the
existing COS and MRS for FGR [7, 9]. Medical experts (ob-
stetricians/gynecologists and neonatologists), researchers,
and parents will be involved in the consensus process, in
line with the recommended methodology of the COMET
initiative. Parent (lay expert) involvement in the whole
process of development and procedure of the COS and
MRS ensures that they include relevant outcomes and items
for the target population. A potential barrier for implemen-
tation could be too many outcomes included in the final
COS, which would make implementation more difficult.
We try to avoid this by stressing exclusivity rather than
inclusivity during the Delphi rounds.
Objective
The objective is to develop an MRS and a COS for inter-
ventional and treatment studies in GRN.
Methods/design
Overview
To develop the Core Outcome Set and Minimum Report-
ing Set for intervention and treatment studies in growth re-
striction in the NEwbOrN (COSNEON) a stepwise
approach will be used according to the COMET handbook,
with some slight amendments [8]. This study will start in
February 2019, with an expected date of completion in
January 2020 (Fig. 1). Our study is registered at the
COMET initiative, accessible via http://www.comet-initia-
tive.org/studies/details/1001?result=true. This protocol was
checked via the SPIRIT checklist (Additional file 1) and via
the COS-STAP checklist (Additional file 2).
Scope of COS determined
The target population for the COS will be growth re-
stricted babies, either diagnosed antenatally (FGR) or
postnatally (GRN). The international consensus defini-
tions of FGR and GRN both apply [1, 10]. We want to de-
velop a single COS for GRN, focused only on
interventions for growth restriction and not considering
preterm birth, a frequent comorbidity, as a COS has
already been developed [11], nor considering prevention
as this is captured by the COS for FGR.
Determine what to measure
First, we will conduct a scoping search strategy to identify
study characteristic items and outcomes reported in inter-
vention and treatment studies following growth restriction
in the newborn in the last five years. The search will be
performed in the database PubMed (search strategy: ((Diet
[tiab] OR Nutritional management [tiab] OR Feeding [tiab]
OR Diet therapy [tiab] OR “Nutrition Therapy”[Mesh] OR
“Therapeutics”[Mesh] OR “Treatment Outcome”[Mesh]
OR therapeutic* [tiab] OR treatment* [tiab] OR treatment
outcome* [tiab] OR intervention* [tiab]) AND (small for
gestational age [tiab] OR intra uterine growth restriction
[tiab] OR IUGR [tiab] OR Very low birthweight [tiab] OR
SGA [tiab] OR Fetal growth restriction [tiab] OR FGR
[tiab] OR Growth restricted fetuses [tiab] OR Fetal growth
retardation [tiab] OR “Fetal Growth Retardation”[Mesh]
OR “Infant, Low Birth Weight”[Mesh] OR growth re-
stricted newborn [tiab] OR GRN[tiab])) Filters: Clinical
Trial; published in the last 5 years; Humans). For each rele-
vant article we will list the study details, baseline character-
istics, and primary/secondary outcome(s), author, title, and
publication year. We will only assess interventional trials
and no observational studies.
Inclusion criteria
– Studies concerning GRN and interventions or
treatments
– Interventional trials
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– The study is published in the last 5 years
Delphi survey
For development of the MRS and COS we will use the
Delphi methodology, an iterative process that narrows
down opinions until consensus is reached on a certain
scientific domain. Several stakeholder groups will be
approached in three survey rounds using RedCAP ver-
sion 7.3.2. The first stakeholder group comprises the lay
experts consisting of parents of infants with GRN and
parents who are expecting GRN (the fetus is diagnosed
as FGR). The second and third groups of stakeholders
consist of professionals. We want to include pediatri-
cians, neonatologists, obstetricians/gynecologists, and
other health professionals whose work focuses on GRN
in the second group and researchers with focus on ba-
bies with GRN in the third group. In the Delphi method
a list of study characteristic items and outcomes is pro-
posed to all participating stakeholders (the ‘partici-
pants’). These are rated for relevance using the Likert
scale (1, really unimportant; 5, really important). After
each round the aggregated results are presented to the
participants, who are then asked to reconsider their
score in light of the majority opinion. On average, two
or three rounds are needed to reach consensus [12].
After the third round, there will be a final consensus
meeting to reach consensus on the MRS and COS.
Recruitment of participants
For the development of the MRS and COS we will include
the previously described experts in the area of intervention
and treatment studies in GRN babies. Selection of the
experts will be by authorship on the topic of fetal growth
restriction/growth restriction of the newborn and interven-
tions, by use of a known group of experts who have been
involved in other Delphi procedures, and by asking
participants to mention other possible experts in the field.
The email will contain a digital flyer with a very brief ex-
planation and an email address and QR link and URL that
links to a more detailed invitation to participate in the
study including an explanation of the study purpose and
details regarding privacy handling (Additional file 3). More-
over, we will produce printable flyers with the QR code,
email, and URL to be disseminated at meetings and confer-
ences. The approach will be in line with privacy regulations
and participants have the option to withdraw at any time.
For recruiting parents of GRN babies we will use an in-
direct approach. We will have posters and flyers inviting
parents to participate at the obstetric/gynecology, pediatric
outpatient clinics, NICUs, at midwifery clinics, and at dif-
ferent GP practices located in Groningen, Amsterdam,
London, and Auckland. Furthermore, patient advisory
groups will be asked to share the study details and the
posters through social media and with their international
patient advocacy contacts. The investigators’ institutional
social media accounts will also be used to advertise the
study. Participants must have adequate English skills and
lay experts will be involved in the wording of the posters
and email. We aim for at least 50 parents completing the
procedure. Before and after each round we will stress the
importance of completing the entire Delphi survey to
ensure good reliability of the results.
Proposed study items and outcomes
The outcomes and study items reported in the studies
identified in the search will be presented to the expert
panel. Additional outcomes/study characteristics that
have been selected for the COS and MRS of GRN and
apply to the postnatal period are also presented to the
panel with the suggestion to include these in this COS
as well.
Fig. 1 SPIRIT figure. This figure depicts the timeline of COSNEON
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Involvement of patient and public
Parents will participate in the Delphi survey procedure,
both in the development of the protocol, design of the
procedure, and in the consensus meeting.
Data collection and analysis
We anticipate a three round Delphi procedure. Each sub-
scribed participant will receive an email with a link to the
online questionnaire. In subsequent rounds the results of
the former round will be presented to the participants.
The results will be presented aggregated at a group level
and no individual answers will be reported. In subsequent
rounds the participants are asked to rate the importance
of the presented aggregated outcomes taking the results of
the former round into consideration. If a participant fails
to respond in a round, he/she will not be invited to the
subsequent round. We will send reminders if a participant
does not respond in two weeks and a final reminder two
days before the deadline. Each round will be open for
three weeks.
First round
The subscribed participants will be invited to participate by
an email with a link to the first round in RedCAP version
7.3.2. They will be asked to score the candidate study char-
acteristic items and outcomes for their relevance. A five-
point Likert scale will be used, slightly different from the
COMET Handbook. A five-point scale rather than a seven-
or a nine-point scale is chosen for a number of reasons
proven from literature, one being that the response rate is
higher using a five-point scale than a seven- or nine-point
scale because it is easier and quicker [13]. The questions
will be grouped into MRS and COS domains. A median
score of 5 is the predefined criterion for the outcome to be
part of the COS/MRS. Additionally the participants are
asked if, in their opinion, any important outcomes were
missed, to ensure that all important outcomes are included
in the MRS and COS. All additional outcomes suggested
by at least two participants will be discussed in the steering
group for inclusion in the subsequent round. We will ask
the participants whether they will possibly be available for
a consensus meeting, with confirmation not essential at
this point in time. In case they are willing to participate we
will provisionally ask them if they will be available to attend
a meeting taking place in Maastricht 17–21 of September
2019 either in person or online through electronic media.
Second round
The results of the first round will be presented in the sec-
ond round. The median of each outcome will be presented
per stakeholder level, visible for all participants regardless
of the stakeholder group to which the participant belongs.
The participant will be asked to re-score the outcomes,
now with the knowledge of the viewpoints of the other
expert stakeholder groups. Again, we will ask for possible
participation in a consensus meeting.
Third round
This is the final round before the consensus meeting.
Results of the previous round will again be presented at
stakeholder level. In this round we ask whether the experts
agree to accept the outcomes with a median Likert of 5
after round two and whether they agree to the rejection of
outcomes with a median Likert less than 4. The predefined
level of agreement is 70%. Participation in a consensus
meeting will now have to be confirmed; all participants at
the consensus meeting will be acknowledged in the manu-
script (after agreement).
Consensus
To finalize COSNEON we will organize two separate
consensus meetings to answer a pressing methodological
matter regarding Delphi procedures in general. At this
point the gold standard is a face-to-face meeting. Con-
sidering the limited funding options for COS and the
ideal of including international experts and lay experts,
we are interested in the option of an electronic meeting.
We aim to investigate whether an electronic consensus
meeting results in the same included variables in the
COS and MRS as a face-to-face meeting. We aim to do
this by organizing one electronic meeting with at least
three representatives of all groups, and a face-to-face
meeting as a satellite meeting of the third Congress of
joint European Neonatal Societies (jENS) on the 17–21
September in Maastricht. All outcomes still included in
the list after round 3 will be taken forward for voting.
Each stakeholder group is of equal importance.
Discussion
We plan to develop both an MRS and a COS for interven-
tion studies in GRN. In our opinion a COS is not sufficient
to compare and aggregate trial data. By only defining the
end output of the trials without properly defining the in-
puts, the quality of the end product cannot be assessed
fully, only the appearance of it. We acknowledge the fact
that interventions in GRN infants are often complicated by
delays in achieving full enteral feeds because of gastrointes-
tinal immaturity and consequent feeding intolerance.
When enteral feeding is not possible, parenteral feeding is
an alternative. However, this carries risks of central-line as-
sociated bloodstream infections and also intestinal failure-
associated liver disease in the case of prolonged parenteral
feeding [14]. These outcomes are highly associated with
preterm birth for which a COS has been developed previ-
ously [11]. Therefore, we chose to develop a COS for inter-
ventions in GRN separately, which is to be combined (with
expected overlap) in studies for preterm GRN babies.
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We will disseminate the COS and MRS via appropriate
media and during relevant international meetings. The
relevance of the COS will also be discussed with patient/
parent organizations. It is vital that the COS and MRS
will be used in future research which focuses on the
GRN. This will increase the relevance of these studies
and it will simplify comparing them.
Additional files
Additional file 1: SPIRIT checklist. (PDF 99 kb)
Additional file 2: COS-STAP checklist. (PDF 43 kb)
Additional file 3: Invitation to participate. (PDF 197 kb)
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